Pathophysiology of Anti‐resorptive Medication‐related Osteonecrosis

Abstract

Osteonecrosis of the jaws (ONJ) is a devastating complication of potent antiresorptive medications utilized for benign and malignant disorders of bone metabolism. Bisphosphonate related ONJ (BRONJ) was first identified in 2003 and 2004, and its prevalence is reported between 0.8–12%. Although significant progress has been made in our understanding of the disease, much more work needs to be done to completely explain its pathophysiology. Many hypotheses have been proposed, which have sparked empirically‐based treatment modalities. It is most likely that the pathophysiology of ONJ is multifactorial, where inflammation/infection and inhibition of bone remodeling are necessary for development of the disease. This presentation will present current evidence for ONJ pathophysiology, and prevention and treatment approaches that can be implemented in the dental office.Support or Funding InformationNIH/NIDCRAmgenThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.